Clinical trials: Hematologic Tests
Epilepsy
Proof of Principle for a Diagnostic Blood Test of Recurrent Seizures
The primary goal of this observational study is to establish the accuracy of CNS-specific Assay for Recurrent Paroxysmal Events (CARPE) as a diagnostic blood test for epilepsy.
- Trial name
- NCT02269397
- Where
- United States
- Volunteers
- 371 people
- Sponsor
- Cognizance Biomarkers, LLC
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma
- Trial name
- NCT02465060
- Testing
- Adavosertib, Afatinib, Afatinib Dimaleate
- Where
- 1,410 sites in United States, Guam and 1 more
- Volunteers
- 6,452 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma Proved by Laboratory Tests
Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China
Intravenous injection is the standard administration route of bortezomib; however, subcutaneous administration is an important alternative.
- Trial name
- MM (NCT01812096)
- Testing
- Subcutaneous bortezomib, Intravenous bortezomib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Transfusion Reactions
Mild Pulmonary Function Changes With Transfusion
The purpose of the study is to determine whether transfusion is associated with mild pulmonary changes.
- Trial name
- NCT00681954
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- University of California, San Francisco
Genotype, Pain
Genetics and Pain Severity in Sickle Cell Disease
Background: Pain is the most common symptom of sickle cell disease. Episodes of severe sickle cell pain are known as "crises." High rates of pain crises are associated with a higher risk of early death.
- Conditions
- Genotype, Pain, Genetic Variation, Quantitative Sensory Testing (QST)
- Trial name
- NCT01441141
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)
This phase II MATCH treatment trial tests how well nivolumab and BMS-986016 (relatlimab) works in treating patients with cancer that has certain genetic changes called LAG-3 mutations with mismatch repair deficiency.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06400264
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Sponsor
- National Cancer Institute (NCI)
Eosinophilic Disorder, Food Allergy
Gastrointestinal STRING Test With Oral Immunotherapy
This STRING study will examine markers of esophageal inflammation using a minimally-invasive testing device, the esophageal string test (EST).
- Trial name
- STRING (NCT04943744)
- Testing
- Entero-tracker, omalizumab, dupliumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Stanford University
Colorectal Cancer
Comparison of Hemoccult, Magstream and OC-Sensor Faecal Occult Blood Tests in Colorectal Cancer Screening
Colorectal cancer screening by faecal occult blood test (FOBT) is a high public health priority. The interest of guaiac tests (G-FOBT) is limited by their poor sensitivity, while the superiority of I-FOBT in comparison with…
- Trial name
- HeMO (NCT01251666)
- Testing
- Colonoscopy
- Where
- 2 sites in France
- Volunteers
- 19,797 people
- Sponsor
- University Hospital, Caen
Muscle-Invasive Bladder Cancer (MIBC), Upper Tract Urothelial Carcinoma
Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper Tract Urothelial Cancer
This prospective observational study evaluates a blood-based circulating tumor DNA (ctDNA) test in patients with muscle-invasive bladder cancer or upper tract urothelial cancer.
- Conditions
- Muscle-Invasive Bladder Cancer (MIBC), Upper Tract Urothelial Carcinoma, Urothelial Carcinoma (UC)
- Trial name
- BLUT-DNA (NCT07756437)
- Where
- Belgium
- Volunteers
- 70 people
- Sponsor
- AZ Sint-Lucas Gent
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)
This phase II MATCH treatment trial identifies the effects of dasatinib in patients whose cancer has a genetic change called DDR2 mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439305
- Testing
- Dasatinib
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Stroke
SMARTCap Stroke Study: A Field Deployable Blood Test for Stroke
The hypothesis is that a stroke causes release of purines from brain into blood and that this is a very early biomarker of brain ischaemia.
- Trial name
- SMARTCAP (NCT02308605)
- Testing
- SMARTCap
- Where
- 2 sites in United Kingdom
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- University Hospitals Coventry and Warwickshire NHS Trust
Multiple Myeloma
Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma
This study will be conducted in 2 parts. The phase 1b part will be an international, phase 1b, open-label, dose-escalation assessment of radium-223 dichloride administered with bortezomib and dexamethasone in subjects with…
- Trial name
- NCT02928029
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Bortezomib, Dexamethasone
- Where
- 7 sites in United States, South Korea and 1 more
- Volunteers
- 7 people
- Sponsor
- Bayer
Colorectal Cancer
Is Barium Enema an Adequate Diagnostic Test for Patients With Positive FOBT?
The research protocol aim is to compare diagnostic tools for the proper evaluation of patient with fecal occult blood test positive (FOBT +), a routine screening test for colorecatl carcinoma.
- Trial name
- DCBE (NCT00619814)
- Testing
- Double-contrast Barium enema, colonoscopy
- Volunteers
- 50 people
- Sponsor
- VA Caribbean Healthcare System
Hodgkin's Disease, Non-Hodgkin Lymphomas
Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy
This investigator initiated trial was a prospective, open, single-arm, diagnostic-prognostic study. Patients who received high-dose therapy with autologous stem cell transplantation for the treatment of their lymphoproliferative…
- Conditions
- Hodgkin's Disease, Non-Hodgkin Lymphomas, Multiple Myelomas
- Trial name
- CU01 (NCT01085058)
- Testing
- lenograstim
- Volunteers
- 169 people
- Sponsor
- WiSP Wissenschaftlicher Service Pharma GmbH
Acute Lymphoblastic Leukemia
A Study in Adults With Untreated Acute Lymphoblastic Leukemia
The purpose of this study is to determine the safety and optimal dosing of L-asparaginase in adult patients with acute lymphoblastic leukemia (ALL) between the ages of 18 and 50 years.
- Trial name
- NCT00136435
- Testing
- prednisone, doxorubicin, vincristine
- Where
- 12 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Dana-Farber Cancer Institute
Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
Ex Vivo Drug Sensitivity Testing and Mutation Profiling
This study is a prospective, non-randomized feasibility study. Freshly isolated tumor cells from patients will be screened using state-of-the-art viability assay designed for ex vivo high-throughput drug sensitivity testing…
- Conditions
- Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large Cell Lymphoma, Refractory Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT03860376
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Florida International University
Colonic Polyp
Study of a Screening Blood Test to Determine Patients' Potential Risk of Adenomatous or Advanced Colon Polyps (ACPs)
The aim of this study is to develop a blood test to determine which patients are at risk for pre-cancerous colon polyps (ACPs: Advanced Colon Polyps).
- Trial name
- NCT01062035
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Ebola Virus Disease, Marburg Virus Disease
Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults
Primary Objective: To evaluate the safety and tolerability of cAd3-EBO-S and cAd3 Marburg vaccines when administered Intramuscular (IM) at a dose of 1 x 10^11 particle units (PU) to healthy adults.
- Trial name
- NCT04723602
- Testing
- cAd3-Marburg, cAd3-EBO-S
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Hepatocellular Carcinoma
Blood Sample Collection for Experimental Blood Test to Track Liver Cancer
This study investigates if an experimental blood test can help predict how well cancer will remain under control with treatment. Ther experimental blood test involves measuring mircoRNAs.
- Trial name
- NCT04720430
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Thomas Jefferson University
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)
This phase II MATCH treatment trial identifiesay block the protein tyrosine kinase WEE1 the effects of AZD1775 in patients whose cancer has a genetic change called BRCA mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439227
- Testing
- Adavosertib
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)